0000313143false00003131432024-07-252024-07-25


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 25, 2024

HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts001-1404104-2882273
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)

125 Summer Street
Boston, MA 02110
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 781-848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $.01 par value per shareHAENew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Explanatory Note

Haemonetics Corporation (the “Company”) filed a Current Report on Form 8-K on July 25, 2024 (the “Original Report”). This amendment to the Original Report (this “Amendment”) amends and restates Item 5.07 of the Original Report in its entirety to correct a clerical error when referencing the Company's current fiscal year in the description of proposal 3. This Amendment does not modify or update any other information set forth in the Original Report.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company’s 2024 Annual Meeting of Shareholders was held on Thursday, July 25, 2024. Of the 50,953,098 shares outstanding and entitled to vote at the meeting, 48,912,250 shares were represented at the meeting, constituting a quorum of 95.99%.

The results of the votes for each proposal considered at the meeting are set forth below:

1. The shareholders elected each of Christopher A. Simon, Robert E. Abernathy, Diane M. Bryant, Michael J. Coyle, Charles J. Dockendorff, Lloyd E. Johnson, Mark W. Kroll, Claire Pomeroy and Ellen M. Zane as directors for one-year terms expiring in 2025 based upon the following votes:

NomineesForWithholdBroker Non-Votes
Christopher A. Simon47,563,311269,3861,079,553
Robert E. Abernathy47,233,098599,5991,079,553
Diane M. Bryant47,637,507195,1901,079,553
Michael J. Coyle47,492,931339,7661,079,553
Charles J. Dockendorff46,789,6431,043,0541,079,553
Lloyd E. Johnson47,243,880588,8171,079,553
Mark W. Kroll46,938,807893,8901,079,553
Claire Pomeroy47,553,094279,6031,079,553
Ellen M. Zane47,122,780709,9171,079,553

2. The shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers based upon the following votes:

ForAgainstAbstainBroker Non-Votes
46,230,4661,460,004142,2271,079,553

3. The shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 29, 2025 based upon the following votes:

ForAgainstAbstain
47,738,7691,049,682123,799





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION
July 30, 2024By:/s/ Christopher A. Simon
Name:Christopher A. Simon
Title:President and Chief Executive Officer


v3.24.2
Document and Entity Information
Jul. 25, 2024
Cover [Abstract]  
Document Type 8-K/A
Document Period End Date Jul. 25, 2024
Entity Registrant Name HAEMONETICS CORPORATION
Entity Central Index Key 0000313143
Amendment Flag false
Entity Incorporation, State or Country Code MA
Entity File Number 001-14041
Entity Tax Identification Number 04-2882273
Entity Address, Address Line One 125 Summer Street
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 781
Local Phone Number 848-7100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $.01 par value per share
Trading Symbol HAE
Security Exchange Name NYSE
Entity Emerging Growth Company false
Haemonetics (NYSE:HAE)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Haemonetics.
Haemonetics (NYSE:HAE)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Haemonetics.